Systematic Reviews
Copyright ©The Author(s) 2017.
World J Radiol. Jul 28, 2017; 9(7): 312-320
Published online Jul 28, 2017. doi: 10.4329/wjr.v9.i7.312
Table 1 Prevalence of distant metastases in patients with invasive breast cancer who had [18]fluorodeoxyglucose-positron emission tomography scan as part of the workup before or immediately after surgery
Ref.Subjects, nStageAge, medianHistologyTumor gradeTumor receptorsDistant metastases2nd primaries
Groheux et al[17]131II: 84NSIDC: 1141: 9ER+: 825.90% (II)1% (II)
III: 47ILC: 82: 5HER2+: 30
T1: 2Other: 93: 53
T2: 71NS: 4
T3: 58
N0: 50
N1: 59
N2: 18
Bernsdorf et al[18]103T2 or55IDC: 831: 11ER+: 748%1.90%
higher(24-81)ILC: 142: 54HER+: 22
Other: 63: 37TN: 13
NS: 1
Choi et al[19]154I: 6952IDC: 141NS: 154NS8.40%NS
II: 51(30-81)ILC: 4
III: 21Other: 9
IV: 13
T1: 89
T2: 51
T3: 14
Garami et al[20]115T1: 5655.7IDC: 921: 16ER+: 896.90%2.60%
T2: 48ILC: 112: 50ER-: 26
NS: 11Other: 123: 48
N0: 57NS: 1
N+: 46
NS: 12
Groves et al[21]70T1: 3461IDC: 451: 02ER+: 642.80%NS
T2: 30ILC: 102: 33HER+: 15
N1: 24Other: 53: 25
Gunalp et al[22]141I: 1947NS2 + 3: 141NS5% (I)NS
II: 100(28-78)30% (II)
III: 14
Pritchard et al[23]325T1: 20756IDC: 2901: 68NS1.50%NS
T2: 110(28-83)ILC: 352: 158
T3: 83: 92
N0: 325
Cochet et al[24]142II: 7951IDC: 1281+2: 81ER+/HER2-: 637.5% (II)NS
III: 46(25-85)ILC: 113: 56HER2+: 33
IV: 17Other: 3NS: 3TN: 31
T2 or
Higher
Jeong et al[25]178N0: 17854.9IDC: 145NSNS0%2.80%
T1: 108(33-82)ILC: 11
T2: 64DCIS: 12
T3: 6Other: 10
Koolen et al[26]62I: 3559.8IDC: 581: 21ER+/HER2-: 4816%3%
II: 25(26-75)ILC: 12: 29TN: 7
III: 2Other: 33: 09HER2+: 7
T1: 62NS: 3
Riedl et al[27]134I: 2036.2IDC: 1241: 01ER+/HER2-: 755% (I)4%
II: 91(22-39)ILC: 12: 23HER2+: 2610.9% (II)
III: 19Other: 93: 110
Zhang et al[28]164T1: 12745IDL: 1501: 23ER+: 1404.80%NS
T2: 35(21-70)ILC: 142-3: 141HER2+: 18
T3: 2
N0: 123
N1: 29
N2: 9
N3: 3
Hogan et al[29]146I: 857ILC: 146NSER+/HER2-: 1320% (I)NS
II: 50(34-92)HER2+: 84% (II)
III: 88TN: 5
Krammer et al[30]101II: 7554IDC: 801: 05ER+: 6715.80%NS
III: 15ILC: 152: 48HER2+: 56
IV: 11Other: 93: 45
T1: 7NS: 6
T2: 69
T3: 4
T4: 5
Nursal et al[31]419I: 10451.5IDC: 305NSNS2.9% (I)NS
II: 315ILC: 2912.4% (II)
T1: 127Other: 85
T2: 270
T3: 20
Ulaner et al[32]232I: 2351IDC: 2172: 8TN: 2320% (I)NS
II: 169(25-93)ILC: 23: 21710% (II)
III: 40NS: 7
Lebon et al[33]214I: 2445.2IDC: 1811: 13HR+/HER2-: 898.3% (I)NS
II: 124ILC: 102: 68HER2+: 6112.9% (II)
III: 66Other: 233: 133TN: 63
NS: 1
Ulaner et al[34]483I: 3652.7IDC: 4141: 5ER+: 4022.8% (I)1.40%
II: 331(23.6-89.5)ILC: 412: 55HER2+: 2459.7% (II)
III: 116Other: 283: 400TN: 024.1% (III)
NS: 23

  • Citation: Vinh-Hung V, Everaert H, Farid K, Djassemi N, Baudin-Veronique J, Bougas S, Michailovich Y, Joachim-Contaret C, Cécilia-Joseph E, Verschraegen C, Nguyen NP. Preoperative [18]fluorodeoxyglucose-positron emission tomography/computed tomography in early stage breast cancer: Rates of distant metastases. World J Radiol 2017; 9(7): 312-320
  • URL: https://www.wjgnet.com/1949-8470/full/v9/i7/312.htm
  • DOI: https://dx.doi.org/10.4329/wjr.v9.i7.312